Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23526183 | 0.93 | TSHR (0.52) | TSHRHTTNR4A2ALDH1A1GAA | |
| SCHEMBL4577829 | 0.90 | NR4A2 (0.56) | TSHRHTTNR4A2ALDH1A1GAA | |
| SCHEMBL29773857 | 0.90 | NR4A2 (0.56) | TSHRHTTNR4A2ALDH1A1GAA | |
| SCHEMBL16961315 | 0.89 | NR4A2 (0.51) | TSHRHTTNR4A2ALDH1A1GAA | |
| SCHEMBL6072552 | 0.85 | ALDH1A1 (0.54) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL30864269 | 0.84 | MAOA (0.53) | TSHRHTTALDH1A1PTGDR2CA12 | |
| SCHEMBL7370270 | 0.84 | DGAT1 (0.53) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL6072378 | 0.82 | NR4A2 (0.49) | TSHRHTTNR4A2ALDH1A1GAA | |
| SCHEMBL6072149 | 0.81 | ALDH1A1 (0.54) | NR4A2ALDH1A1GAAL3MBTL1HSD17B10 | |
| SCHEMBL3839211 | 0.81 | NR4A2 (0.54) | TSHRHTTNR4A2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4463462-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885HTT 1359/4885NR4A2 3794/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885HTT 1359/4885NR4A2 3794/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | TSHR 2377/4885HTT 1359/4885NR4A2 3794/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | TSHR 437/4885HTT 1417/4885NR4A2 4035/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | TSHR 204/4885HTT 462/4885NR4A2 3190/4885 |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885HTT 1359/4885NR4A2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.